CNBS ETF

Amplify's CNBS ETF has shifted focus to American cannabis and hemp, making it a better option than MSOS due to its more diversified structure. CNBS's portfolio is less concentrated in a few stocks compared to MSOS, reducing risk and offering better potential for long-term performance. Risks include 280E taxation remaining, CNBS's smaller size, and limited liquidity, but Tim Seymour's active management is a positive factor.

The Canadian cannabis sector is currently experiencing a period of consolidation, as poorly managed companies face challenges and the industry reaches a more mature stage.

In a White House meeting, Vice President Kamala Harris this week urged the DEA to expedite the rescheduling of marijuana, criticizing its current Schedule 1 classification as "absurd" and "patently unfair." She put stress on the need for swift action and highlighted ongoing efforts toward rescheduling.

Cannabis stocks & ETFs jumped on Mar 15 after a prominent hedge fund manager suggested that regulators will soon reclassify marijuana as a less dangerous drug.

The cannabis sector continues to entice investors with its prospects for expansion and financial success as we take on the last quarter of 2023. Cannabis Exchange-Traded Funds (ETFs) have become popular for investors seeking exposure to this dynamic sector while keeping a diversified portfolio. The best Cannabis ETFs to watch in 2023's fourth quarter will be examined in this piece, along with their dividend yields and suitability for both long- and short-term trading approaches.

Like any recovering reporter, I like to keep tabs on my old beats, and the marijuana ETF space never disappoints. Or, perhaps more accurately, it never stops disappointing.

In 2023, the cannabis industry and top marijuana stocks are blazing a trail of exponential growth, presenting investors with a unique opportunity to tap into this flourishing sector. As regulatory landscapes evolve and societal attitudes toward marijuana become more accepting, the market for cannabis-related products expands at an unprecedented rate.

In a significant development, the Department of Health and Human Services (HHS) has recently initiated a review of marijuana's classification under the Controlled Substances Act.

Possible cannabis reclassification fuels fund optimism.